Zenas BioPharma (NASDAQ:ZBIO) Earns “Sell (D-)” Rating from Weiss Ratings

Zenas BioPharma (NASDAQ:ZBIO)‘s stock had its “sell (d-)” rating restated by equities researchers at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

Separately, Wall Street Zen cut shares of Zenas BioPharma from a “hold” rating to a “sell” rating in a research note on Friday, September 26th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $38.33.

Zenas BioPharma Stock Up 7.2%

ZBIO stock opened at $27.76 on Wednesday. The stock has a market capitalization of $1.17 billion and a P/E ratio of -7.82. The firm has a 50-day simple moving average of $18.64 and a 200-day simple moving average of $13.24. Zenas BioPharma has a 52 week low of $5.83 and a 52 week high of $28.72.

Zenas BioPharma (NASDAQ:ZBIO) last released its earnings results on Tuesday, August 12th. The company reported ($1.25) EPS for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.23).

Insider Activity at Zenas BioPharma

In other Zenas BioPharma news, insider Leon O. Moulder, Jr. acquired 36,928 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The stock was bought at an average price of $20.85 per share, with a total value of $769,948.80. Following the purchase, the insider owned 36,928 shares in the company, valued at approximately $769,948.80. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Hongbo Lu acquired 263,160 shares of the company’s stock in a transaction that occurred on Tuesday, October 7th. The shares were acquired at an average cost of $19.00 per share, with a total value of $5,000,040.00. Following the purchase, the director owned 321,983 shares in the company, valued at $6,117,677. This represents a 447.38% increase in their position. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 616,307 shares of company stock valued at $11,778,150. Corporate insiders own 16.50% of the company’s stock.

Hedge Funds Weigh In On Zenas BioPharma

Institutional investors and hedge funds have recently bought and sold shares of the company. Nuveen LLC acquired a new position in Zenas BioPharma in the 1st quarter valued at about $250,000. New York State Common Retirement Fund acquired a new position in Zenas BioPharma in the 1st quarter valued at about $49,000. Jefferies Financial Group Inc. acquired a new position in Zenas BioPharma in the 1st quarter valued at about $348,000. Geode Capital Management LLC boosted its holdings in Zenas BioPharma by 4.6% in the 2nd quarter. Geode Capital Management LLC now owns 373,617 shares of the company’s stock valued at $3,621,000 after purchasing an additional 16,461 shares during the last quarter. Finally, Rhumbline Advisers boosted its holdings in Zenas BioPharma by 71.3% in the 2nd quarter. Rhumbline Advisers now owns 19,721 shares of the company’s stock valued at $191,000 after purchasing an additional 8,207 shares during the last quarter.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.